Form D · Other
Kaneh Bosm Biotechnology Inc.
Vancouver, A1 · CIK 0001743067
Offering snapshot reported Jul 12, 2018 · SEC filing
- Reported sold
- $2.5M Offering amount: $2.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 28, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 12, 2018 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
| Jun 21, 2018 | Initial | $5,901,815 | No comparison | 3 | SEC filing |
| Jun 11, 2018 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-316747
Nil
Source: Form D, filed Jul 12, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kent Ausburn | Director |
| Eugene Beukman | Director, Executive |
| Rudy De Jonge | Director, Executive |
| Michael Martinz | Director |
| Peter Nguyen | Executive |
| Brendan Purdy | Director |
Issuer details
Industry: Other (See others in industry)
Address:
810 789 West Pender Street
Vancouver, A1, V6C1H2
Vancouver, A1, V6C1H2